GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Certara Inc.
Certara provides biosimulation software that helps pharmaceutical companies model drug performance. Its stock price reflects the trend toward using technology to speed up and reduce the cost of drug development.
Share prices of companies in the market segment - It med
Certara provides biosimulation software used by pharmaceutical companies to accelerate drug development. Its core business is subscription software. We classify the company as part of the IT med sector, and the chart below reflects the dynamics of the entire medical technology and software industry.
Broad Market Index - GURU.Markets
Certara is a company that uses computer modeling and simulation to accelerate drug development. Its technology earns it a spot in the GURU.Markets index. The chart below represents the market. See how Certara's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
CERT - Daily change in the company's share price Certara Inc.
For Certara, a drug development modeling software provider, change_co is a measure of volatility in biotech. Daily fluctuations reflect pharmaceutical companies' demand for accelerated R&D. This metric is important for analyzing healthcare service companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - It med
Certara, Inc. is a company providing software and services for drug development. This chart shows the average daily volatility of the healthcare sector. Compared to CERT, whose revenue depends on pharmaceutical companies' R&D budgets, it serves as a barometer of innovation.
Daily change in the price of a broad market stock, index - GURU.Markets
Certara provides biosimulation software and services to accelerate drug development. Its business serves as a barometer of activity in the global pharmaceutical industry. The chart below shows general market fluctuations, which can be used to assess Certara's stability.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Certara Inc.
Certara uses modeling and simulation software in the drug development process, helping pharmaceutical companies save time and money. Its annual growth rate serves as a barometer of R&D investment in the biotech industry.
Annual dynamics of market capitalization of the market segment - It med
Certara, Inc. provides biosimulation software that helps pharmaceutical companies accelerate drug development. Its technology is becoming an industry standard. The chart below shows how its key role in R&D, its subscription model, and rising drug development costs are impacting its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Certara, with its drug development modeling software, is a gold mine for biotech. Demand for its services isn't dependent on the economy, but rather is driven by pharmaceutical companies' R&D budgets. The company's stock price reflects the long-term trend toward faster and cheaper drug development, making it a defensive technology bet.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Certara Inc.
The performance of Certara, a company that uses simulation in drug development, depends on the R&D cycles in the pharmaceutical industry. The monthly fluctuations on the chart reflect the demand for its software and consulting services from pharmaceutical companies seeking to accelerate and reduce the cost of developing new drugs.
Monthly dynamics of market capitalization of the market segment - It med
This chart reflects the dynamics of the pharmaceutical software sector. For Certara, a leader in biosimulation, it provides context. Its movements demonstrate how the trend toward faster and cheaper R&D is driving demand for its clinical trial simulation platforms.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Certara, Inc. provides modeling and simulation software for drug development. Its clients are pharmaceutical companies with stable R&D budgets. This makes Certara's business resilient to economic cycles, and its stock price less sensitive to general market fluctuations.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Certara Inc.
Certara, Inc. provides biosimulation software used by pharmaceutical companies to model drug performance and optimize clinical trials. Its weekly stock price reflects R&D spending in the pharmaceutical industry and the trend toward using technology to accelerate drug development.
Weekly dynamics of market capitalization of the market segment - It med
Certara, as a software provider for the pharmaceutical industry, moves at the pace of the sector. Its dynamics depend on R&D spending. The chart allows us to compare it with biotech companies and see whether the technology provider is more or less volatile than its clients, whose fate depends on the success of their drugs.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Certara uses computer modeling to optimize drug development. It's a "pick and shovel" for the pharmaceutical industry. The chart shows how its shares, despite being a B2B growth story, are more volatile than the market.
Market capitalization of the company, segment and market as a whole
CERT - Market capitalization of the company Certara Inc.
Certara's market capitalization reflects its leadership in biosimulation—the use of computer modeling to predict how drugs will behave in the body. Its chart shows how investors value its software, which helps pharmaceutical companies speed up and reduce the cost of drug development.
CERT - Share of the company's market capitalization Certara Inc. within the market segment - It med
Certara, Inc. is a market leader in biosimulation—the use of computer modeling to predict drug performance. Its dominant market share means its software is used by nearly all leading pharmaceutical companies to accelerate R&D.
Market capitalization of the market segment - It med
Here's a chart showing the market capitalization of the pharmaceutical research sector. Certara is a leader in model-driven drug discovery. Its software predicts drug behavior in the body, accelerating and reducing the cost of drug development. The growth of this market reflects the pharmaceutical industry's commitment to improving R&D efficiency.
Market capitalization of all companies included in a broad market index - GURU.Markets
Certara uses computer modeling and simulation to accelerate drug development. Its market capitalization reflects the trend toward digitalization in the pharmaceutical industry. The chart below shows the economic weight of the biotech IT services sector.
Book value capitalization of the company, segment and market as a whole
CERT - Book value capitalization of the company Certara Inc.
Certara's foundation is its software and biosimulation platform, which are used by pharmaceutical companies to predict how drugs will behave in the human body. The chart shows how this science-intensive IT company is growing its intangible assets, helping to speed up and reduce the cost of developing new drugs.
CERT - Share of the company's book capitalization Certara Inc. within the market segment - It med
Certara uses modeling and simulation to accelerate drug development. The chart shows its share of physical IT assets. Its infrastructure includes powerful computing clusters that enable drug prediction, reducing the need for real-world experiments.
Market segment balance sheet capitalization - It med
Certara, Inc. provides biosimulation software for the pharmaceutical industry. Its business is asset-light. The company's value lies in its software products and databases, not in its laboratories or manufacturing facilities. Compared to the healthcare sector as a whole, its model allows for accelerated R&D without investing in wet labs.
Book value of all companies included in the broad market index - GURU.Markets
Certara's assets aren't drugs, but cutting-edge biosimulation software that allows pharmaceutical companies to predict drug performance before clinical trials begin. The balance sheet reflects the value of these "virtual patients." The chart shows how much capital has been invested in technologies that accelerate drug development.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Certara Inc.
Certara uses computer modeling to accelerate drug development. Its value lies not in its servers, but in its software and data, which have become industry standards. Its market capitalization reflects its key role in reducing the costs and risks of developing new drugs.
Market to book capitalization ratio in a market segment - It med
Certara provides modeling and simulation software for pharmaceutical development. Its value lies in its unique software, which helps accelerate drug discovery. This chart shows the premium investors pay for its key role in pharmaceutical companies' R&D processes.
Market to book capitalization ratio for the market as a whole
Certara provides software and consulting services to the biopharmaceutical industry, helping to optimize drug development. It's a knowledge-intensive technology business. The chart shows the market premium paid for a company whose technologies help speed up and reduce the cost of developing new drugs.
Debts of the company, segment and market as a whole
CERT - Company debts Certara Inc.
Certara provides software and services for modeling and simulation in pharmaceutical development, helping to accelerate the discovery of new drugs. The company uses its capital to invest in its technologies and to acquire other companies that expand its scientific and consulting capabilities for biotech and pharmaceutical clients.
Market segment debts - It med
Certara, Inc. provides biosimulation software used by pharmaceutical companies to accelerate drug development. This is a niche but important sector of healthcare IT. This chart shows how the company funds the development of its specialized software and how its subscription-based financial model ensures stability.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Certara Inc.
Certara provides software and services for modeling and simulation in drug development. This chart illustrates its research-intensive business model. Its debt level reflects its growth strategy, which includes acquisitions to expand its capabilities and strengthen its position as a key partner for the pharmaceutical industry.
Market segment debt to market segment book capitalization - It med
Certara provides software and consulting services to the biopharmaceutical industry, helping optimize drug development. This chart reflects debt trends in the healthcare IT sector. It helps understand how the company finances its technology platforms and growth in a market where accelerating R&D is a key value.
Debt to book value of all companies in the market
Certara, working at the intersection of software and pharmaceuticals, serves the innovative industry. The chart reflects debt trends across the economy. It helps understand how the sector accelerating drug development is growing independently of overall economic cycles, driven by the demand for new treatments.
P/E of the company, segment and market as a whole
P/E - Certara Inc.
This chart for Certara, a pharmaceutical simulation software provider, is a bet on the digitalization of drug development. Investors' high earnings estimates reflect their belief that pharmaceutical companies will increasingly use simulations to speed up and reduce the cost of R&D. The trend reflects the adoption of these technologies in the industry.
P/E of the market segment - It med
This chart shows the average valuation for the pharmaceutical IT services sector—a benchmark for Certara. The high valuation across the industry reflects a belief in the digitalization of R&D. Comparison with this metric helps understand whether investors consider Certara a key player in this transformation and are willing to pay a premium for its software.
P/E of the market as a whole
Certara provides biosimulation software and services, helping pharmaceutical companies accelerate and reduce the cost of drug development. The company's growth depends on outsourcing R&D within the pharmaceutical industry. This chart of overall sentiment in the biotech and pharmaceutical sectors shows how actively companies are willing to invest in new technologies to optimize their research.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Certara Inc.
Certara, Inc. provides biosimulation software used by pharmaceutical companies to model drug performance and optimize clinical trials. The company's growth is driven by the pharmaceutical industry's desire to reduce development costs. This chart shows analysts' expectations for the further integration of modeling technologies into R&D.
%20P%2FE%20Certara%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Certara-Inc.&v=1772651216541 "Chart of the company's future (projected) P/E Certara Inc.")
Future (projected) P/E of the market segment - It med
Certara provides software and services for modeling and simulation in pharmaceutical development, helping to accelerate the development of new drugs. Its valuation relative to other healthcare IT companies reflects investors' belief that its technologies are becoming the standard in R&D. The high valuation reflects expectations for further adoption of its platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-It-med&v=1772651216557 "Future (projected) P/E graph of the market segment - It med")
Future (projected) P/E of the market as a whole
Certara provides modeling and simulation software for drug development, helping pharmaceutical companies make more informed decisions. Its business depends on R&D spending in the pharmaceutical industry. This chart reflects the overall sentiment in the healthcare sector, demonstrating the extent to which investors believe in the future of pharma and its ability to innovate.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772651216577 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Certara Inc.
Certara provides biosimulation software and services, helping pharmaceutical companies accelerate drug development. The financial results shown in this chart are driven by R&D spending in the pharmaceutical industry. Its tools enable drug simulation, reducing the need for costly testing.
Profit of companies in the market segment - It med
Certara, Inc. uses computer modeling and simulation to speed up and reduce the cost of drug development (biosimulation). This chart shows the overall profitability of the healthcare IT services sector. It demonstrates the pharmaceutical industry's willingness to adopt advanced technologies to optimize its R&D processes.
Overall market profit
Certara uses computer modeling and simulation to optimize the drug development process. It helps pharmaceutical companies make more informed decisions and reduce costs. Demand for CERT's services is growing as the pharmaceutical industry strives to improve R&D efficiency. This need is relevant regardless of the economic cycle.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Certara Inc.
Certara provides biosimulation software that helps pharmaceutical companies model drug performance and optimize clinical trials. Its revenue is driven by R&D spending in the pharmaceutical industry. This chart shows analysts' expectations for the increased adoption of in silico technologies to accelerate and reduce the cost of drug development.
%20profit%20of%20the%20company%20Certara%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Certara-Inc.&v=1772651216889 "Graph of future (projected) profit of the company Certara Inc.")
Future (predicted) profit of companies in the market segment - It med
Certara, Inc. provides biosimulation software and services to the pharmaceutical industry. Their technologies help simulate drug action in the body, speeding up and reducing the cost of drug development. This chart shows forecasts for the healthcare IT sector. It illustrates how digitalization and the use of models for decision making are changing the drug discovery process.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-It-med&v=1772651216904 "Graph of future (predicted) profits of companies in a market segment - It med")
Future (predicted) profit of the market as a whole
Certara, Inc. provides biosimulation software and services for drug development. This projected revenue curve impacts pharmaceutical companies' R&D budgets. Economic growth allows pharma giants to invest more in accelerating and improving the efficiency of new drug development using cutting-edge technologies like Certara's platform.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772651216912 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Certara Inc.
Certara uses modeling and simulation software in the drug development process, helping pharmaceutical companies make more informed decisions. This chart shows how investors value its revenue, betting that its technologies will become the standard in R&D.
P/S market segment - It med
Certara uses biosimulation and technology to speed up and reduce the cost of drug development. This chart shows the average valuation in the IT healthcare sector. It reflects the premium investors are willing to pay for software and services that help pharmaceutical companies make more informed decisions and bring drugs to market faster.
P/S of the market as a whole
Certara, Inc. provides biosimulation software used by pharmaceutical companies to model drug performance and optimize clinical trials. Revenue is growing due to demand for faster drug development. This chart helps assess the market premium for IT solutions that improve efficiency in the pharmaceutical industry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Certara Inc.
Certara, Inc. provides biosimulation software and services that help pharmaceutical companies accelerate drug development. Future revenue is driven by R&D spending in the pharmaceutical industry. The chart reflects investors' belief that Certara's technologies are becoming an integral part of the drug discovery process.
%20P%2FS%20Certara%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Certara-Inc.&v=1772651216933 "The graph of the company's future (projected) P/S Certara Inc.")
Future (projected) P/S of the market segment - It med
Certara, Inc. provides biosimulation software and services used by pharmaceutical companies to model drug performance and optimize clinical trials. It helps accelerate drug development. This chart shows how the market estimates its future revenue compared to other healthcare IT solution providers.
%20P%2FS%20market%20segment%20graph%20-%20It%20med&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-It-med&v=1772651216947 "Future (projected) P/S market segment graph - It med")
Future (projected) P/S of the market as a whole
This chart shows general expectations for the pharmaceutical industry. For Certara, a company that provides modeling software for drug development, it's an indicator of R&D activity. Market optimism allows pharmaceutical companies to invest more in research, using Certara's tools to accelerate and improve efficiency.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772651216951 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Certara Inc.
Certara provides software and consulting services to the biopharmaceutical industry, using modeling and simulation to optimize the drug development process. This chart shows revenue from software licensing and contract fulfillment. Growing revenue indicates that more and more pharmaceutical companies are using Certara's technology to accelerate drug delivery to market.
Sales of companies in the market segment - It med
Certara, Inc. provides biosimulation software and services used by pharmaceutical companies to model drug performance. This chart illustrates the dynamics of the healthcare IT sector. Certara helps accelerate drug development and improve its efficiency, a key element in modernizing the pharmaceutical industry.
Overall market sales
Certara, Inc. provides biosimulation software used by pharmaceutical companies to accelerate drug development. Demand for its products depends on R&D spending in the pharmaceutical industry. This trend in overall economic activity influences the budgets of large pharmaceutical companies and their willingness to invest in technologies to improve efficiency.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Certara Inc.
Certara provides biosimulation software and consulting services used by pharmaceutical companies to accelerate drug development. The company's growth is driven by the need to improve R&D efficiency in the pharmaceutical industry. This graph reflects analysts' expectations for the implementation of modeling technologies in the drug discovery process.
%20sales%20of%20the%20company%20Certara%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Certara-Inc.&v=1772651216996 "Schedule of future (projected) sales of the company Certara Inc.")
Future (projected) sales of companies in the market segment - It med
Certara, Inc. provides software and consulting services to the biopharmaceutical industry, helping to optimize drug development. This forecast outlines expectations for the healthcare IT sector, reflecting the growing use of computer modeling to accelerate and reduce the cost of developing new drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-It-med&v=1772651217003 "Schedule of future (projected) sales of companies in the market segment - It med")
Future (projected) sales of the market as a whole
Certara, Inc. provides biosimulation software and services used by pharmaceutical companies to accelerate drug development. Demand for its products depends on the volume of R&D in the pharmaceutical industry. This dynamic, reflecting the overall economic situation, influences the R&D budgets pharmaceutical companies are willing to allocate to new projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772651217025 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Certara Inc.
Certara provides biosimulation software that helps pharmaceutical companies accelerate drug development. This chart shows the profitability of selling digital R&D solutions. The company's revenue comes from software subscriptions and consulting services, which save pharmaceutical giants millions of dollars in failed trials.
Market segment marginality - It med
Certara, Inc. provides biosimulation software and services used by pharmaceutical companies to accelerate drug development. Profitability depends on the integration of its technologies into R&D processes. This chart illustrates the success of Certara's business model in the life sciences IT solutions niche.
Market marginality as a whole
Certara provides software and consulting services for biosimulation in pharmaceutical development. This overall market profitability chart is not directly relevant to the company. Its clients—pharma companies—invest in research and development regardless of economic cycles. Certara helps them accelerate and reduce the cost of this process, increasing their own R&D efficiency.
Employees in the company, segment and market as a whole
Number of employees in the company Certara Inc.
Certara uses computer modeling and simulation to accelerate and improve the efficiency of drug development. The graph shows a team of scientists and consultants who help pharmaceutical companies make better decisions. The growth of the team reflects the increasing adoption of these technologies in R&D.
Share of the company's employees Certara Inc. within the market segment - It med
Certara, Inc. uses biosimulation and modeling to accelerate drug development. This chart shows the percentage of highly qualified pharmacologists, mathematicians, and data scientists the company attracts in the model-driven drug discovery niche. It reflects its leadership and concentration of unique scientific talent, which is in demand across the pharmaceutical industry.
Number of employees in the market segment - It med
Certara, Inc. provides biotechnology software and consulting services to accelerate drug development. Its biosimulation platform simulates drug action in the body, reducing the time and cost of clinical trials. This chart reflects employment growth in the healthcare IT solutions sector, demonstrating how technology is transforming the pharmaceutical industry.
Number of employees in the market as a whole
Certara provides software and consulting services for the biopharmaceutical industry, helping to optimize the drug development process through modeling. Their technologies accelerate research and reduce costs. This is an example of how IT solutions are transforming even knowledge-intensive industries like pharmaceuticals, increasing their efficiency.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Certara Inc. (CERT)
Certara provides modeling and simulation software for drug development. This chart illustrates how technology is transforming pharmaceuticals. Their very high capitalization per employee demonstrates that their software, which saves billions on clinical trials, creates enormous value for the entire industry.
%20of%20the%20company%20Certara%20Inc.%20(CERT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Certara-Inc.-CERT&v=1772651217158 "Chart of market capitalization per employee (in thousands of dollars) of the company Certara Inc. (CERT)")
Market capitalization per employee (in thousands of dollars) in the market segment - It med
Certara (CERT) provides biosimulation software (modeling drug effects) and consulting services to pharmaceutical companies, helping accelerate R&D. This chart shows the average market capitalization per employee in the sector. It helps assess how much the market values their niche software and scientific expertise (services) per specialist.
%20by%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-It-med&v=1772651217188 "Market capitalization per employee (in thousands of dollars) by market segment - It med")
Market capitalization per employee (in thousands of dollars) for the overall market
Certara, Inc. provides biosimulation software used in drug development. This chart reflects the average value the market assigns to one employee. It demonstrates the high valuation of technologies that help speed up and reduce the cost of developing new drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772651217209 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Certara Inc. (CERT)
Certara provides software and consulting for biosimulation (modeling drug action). This helps accelerate pharmaceutical R&D. This chart shows how efficiently their scientists and software developers generate revenue. It's a highly intelligent business, where every employee is a valuable asset.
%20Chart%20Certara%20Inc.%20(CERT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Certara-Inc.-CERT&v=1772651217227 "Company Profit Per Employee (in thousands of dollars) Chart Certara Inc. (CERT)")
Profit per employee (in thousands of dollars) in the market segment - It med
Certara (CERT) is a vertical SaaS (software for clinical trial simulation). This chart shows the benchmark for "Medical IT." The average profit per employee here is astronomical. The sector provides "sticky," mission-critical, regulated software for which clients (pharma companies) pay huge sums.
%20in%20the%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-It-med&v=1772651217254 "Chart of profit per employee (in thousands of dollars) in the market segment - It med")
Profit per employee (in thousands of dollars) for the market as a whole
Certara is a company that provides biosimulation software and services. They help pharmaceutical companies simulate drug performance on computers, accelerating R&D. It's a niche "techbio" service. This graph shows how in-demand their software and services (highly paid consultants) are for Big Pharma, and how scalable this model is.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772651217278 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Certara Inc. (CERT)
Certara provides software and consulting services to the biopharmaceutical industry, accelerating drug development. This chart illustrates the value of data and modeling in modern pharmaceuticals. It shows how the company's experts help save time and money while generating high revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Certara-Inc.-CERT&v=1772651217286 "Sales chart per company employee Certara Inc. (CERT)")
Sales per employee in the market segment - It med
Certara provides biosimulation software and services, helping pharmaceutical companies model drug performance and accelerate R&D. It's a knowledge-intensive IT business. This chart shows the average revenue per employee in the segment. It helps evaluate how effectively Certara's team (scientists and developers) sells its software and expertise compared to competitors.
Sales per employee for the market as a whole
Certara is a company that provides software and consulting for biosimulation. They help pharmaceutical companies model drug performance, accelerating R&D. This graph shows how productive their highly skilled employees (scientists and programmers) are. They generate revenue by selling their unique intellectual property and expertise.
Short shares by company, segment and market as a whole
Shares shorted by company Certara Inc. (CERT)
Certara provides software and services for clinical trial modeling (biosimulation), helping pharmaceutical companies optimize drug development. It's a complex, science-intensive business. This chart shows the percentage of "bears" who doubt the real savings from Certara's services or expect a slowdown in biotech R&D budgets.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Certara-Inc.-CERT&v=1772651217362 "Short Shares Chart for the Company Certara Inc. (CERT)")
Shares shorted by market segment - It med
Certara, Inc. provides biosimulation software used by pharmaceutical companies to model clinical trials and predict drug performance. This chart shows the overall short position in the healthcare IT services sector. Its rise suggests investor doubts about the continued high R&D spending in biotech or the effectiveness of the software itself.
Shares shorted by the overall market
Certara (CERT) is a SaaS company that models drug trials for biotechs. This Short_All chart shows "risk aversion." This pessimism is drying up funding for biotechs (CERT's clients). As a result, they have no money left over for outsourcing R&D—Certara's core business.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Certara Inc. (CERT)
Certara (CERT) provides software and services for modeling in drug development (biosimulation). Its business relies on pharmaceutical companies' R&D budgets. This chart, above 70, may reflect strong demand from biotech. A range below 30 is often associated with concerns about a slowdown in R&D (a "venture winter") or increased competition.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Certara-Inc.-CERT&v=1772651217418 "RSI 14 indicator chart for the company's stock Certara Inc. (CERT)")
RSI 14 Market Segment - It med
Certara (CERT) is a "biosimulation" company. Their software allows pharmaceutical companies to *simulate* drug trials on a computer, saving billions on R&D. RSI_14_Seg for "It med" (medical IT) shows the "temperature" of the sector. It helps us understand: is CERT's growth due to their unique technology or the general "overheating" of the biotech software sector?
RSI 14 for the overall market
Certara (CERT) provides clinical trial modeling software. This chart is an indicator of R&D budgets in the pharma industry. In the euphoria of biotech, funding is generous and spent on Certara software to accelerate R&D. In a panic, the funding for biotech is shut off, and budgets for "auxiliary" software are cut.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CERT (Certara Inc.)
Certara (CERT) provides biosimulation software that allows pharmaceutical companies to simulate how drugs work in the body before expensive trials. This chart shows the average target price. It reflects analysts' views on the growth of biotech R&D budgets and the adoption of technologies to accelerate drug development.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CERT-Certara-Inc.&v=1772651217518 "A chart showing analyst consensus forecasts for the expected stock price. CERT (Certara Inc.)")
The difference between the consensus estimate and the actual stock price CERT (Certara Inc.)
Certara is a software-based biotech company. The company creates biosimulation software that (using AI) predicts how drugs will behave in the body, accelerating pharmaceutical R&D. This chart shows the difference between the consensus estimate and the price. It reflects whether analysts believe in this SaaS model for R&D and see its potential.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CERT-Certara-Inc.&v=1772651217554 "A chart showing the difference between the consensus forecast and the actual stock price. CERT (Certara Inc.)")
Analyst consensus forecast for stock prices by market segment - It med
Certara is a leader in biosimulation. Its software allows pharmaceutical companies to create "virtual patients" and simulate drug effects, accelerating clinical trials. This chart shows general expectations for the healthcare IT sector, reflecting experts' belief in the further digitalization of drug development.
Analysts' consensus forecast for the overall market share price
Certara, Inc. provides biosimulation (modeling) software for the pharmaceutical industry. Their software predicts how a drug will behave in the body, saving time and money on R&D. This chart shows the overall market sentiment. For Certara, a SaaS company operating in the defense pharmaceutical sector, the overall optimism is important, as it supports high valuations in the IT sector.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Certara Inc.
Certara is an invisible partner for the pharmaceutical industry. They are leaders in biosimulation (software-based modeling)—software that predicts how a drug will behave in the human body before expensive clinical trials begin. This chart is an assessment of their digital R&D platform. It reflects their sticky subscription model and the growing adoption of AI to accelerate drug development.
AKIMA Market Segment Index - It med
Certara (CERT) is a leader in biosimulation; the company provides mission-critical software (SaaS) and consulting to pharmaceutical companies, enabling them to simulate clinical trials on the computer. This aggregate metric evaluates companies. The graph shows the average value for the software segment. This benchmark: how does Certara's indispensable (R&D) role differentiate it from the average competitor?
The AKIM Index for the overall market
Certara is a leader in biosimulation. Its software enables computer simulation of drug effects, accelerating clinical trials. This chart, reflecting the market average, is a backdrop. It helps assess how this "defensive" IT business for pharma, which increases R&D efficiency, compares to general macroeconomic fluctuations.
